Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in <scp><i>RAS</i></scp>‐mutant relapsed or refractory myeloid malignancies

Abstract

The selective, single-agent activity of trametinib against RAS-mutated myeloid malignancies validates its therapeutic potential. Combination strategies based on a better understanding of the hierarchical role of mutations and signaling in myeloid malignancies are likely to improve the response rate and duration. Cancer 2016;122:1871-9. © 2016 American Cancer Society.